Scope and claims analysis for US Drug Patent 12,239,653 (cedazuridine/decitabine oral solid dose providing 20 mg/m² IV-equivalent 5-day decitabine AUC)
US 12,239,653 is a method-of-treatment patent that ties clinical use of decitabine (a nucleoside analog) to a specific oral fixed-dose solid formulation of cedazuridine plus decitabine and to a pharmacokinetic equivalence metric. The claim scope is narrow on formulation composition and dose (100 mg cedazuridine and 35 mg decitabine) and narrow on PK performance (5-day AUC equivalent to 20 mg/m² IV decitabine given as a 1-hour infusion). It is broader than a pure formulation patent because it is written as a method of treating disorders “treatable with decitabine,” then narrowed through dependent claim recitations to hyperproliferative disorders and enumerated cancer subtypes, with an additional dependent narrowing to lower-risk MDS by IPSS categories.
What exactly does US 12,239,653 claim: cedazuridine/decitabine oral dosing with decitabine AUC equivalence?
Core independent claim scope (Claim 1)
Claim 1 covers a method of treating any disorder that is “treatable with decitabine,” when the treatment is delivered by:
- A solid oral dosage form that is defined by its exact composition components (active(s) plus excipients), and
- A specific daily dose content inside that form:
- 100 mg cedazuridine
- 35 mg decitabine
- Optionally coated dosage form (coating not required).
- Pharmacokinetic equivalence requirement: after daily administration to a human, the formulation produces plasma levels of decitabine with a 5-day AUC for decitabine that is equivalent to the 5-day AUC for an intravenous dose of decitabine of 20 mg/m² administered as a 1-hour infusion, and
- That equivalently dosed decitabine exposure treats the disorder.
Legal effect of the PK equivalence limitation
The AUC equivalence requirement is a major scoping element. It is not simply that the patient receives 20 mg/m² by IV; it is that the oral regimen produces an AUC equivalent to that benchmark over five days. That tends to:
- Anchor claim coverage to specific exposure dynamics attributable to the formulation and dosing regimen.
- Create infringement arguments that can hinge on pharmacokinetic study results comparing oral exposure versus IV exposure.
Because the metric is “5-day AUC” and the IV comparator includes dosing strength (20 mg/m²) and infusion duration (1 hour), the claim implicitly assumes a comparable dosing schedule across days 1–5. If an accused product does not meet AUC equivalence, the method claim may be avoided even if the product contains cedazuridine and decitabine.
Formulation boundaries in Claim 1: what is covered and what is not
Claim 1 recites a “solid oral dosage form consisting of” the listed ingredients. In US claim construction, “consisting of” typically excludes additional components beyond those specified.
What is not plainly covered
Any oral solid formulation that materially changes:
- the active amounts (not 100 mg/35 mg),
- the specified excipients,
- or the “solid oral dosage form consisting of” boundary
would likely fall outside the claim, even if it achieves similar PK outcomes.
How does US 12,239,653 narrow “decitabine-treatable disorders” to specific cancers and subtypes?
Claim 1 is a broad functional hook: “a disorder that is treatable with decitabine.” Claims 2–10 progressively narrow the treated disorder category.
Claim 2: hyperproliferative disorders
Claim 2 requires the disorder be a hyperproliferative disorder. This is still broad across many oncology indications, but it excludes non-hyperproliferative uses.
Claims 3–4: cancer category and cancer types
- Claim 3 limits to cancer.
- Claim 4 limits cancer to:
- hematological cancers and solid cancers.
Claim 5: enumerated hematological cancers
Claim 5 lists hematological cancers as selected from:
- myelodysplastic syndromes (MDS)
- leukemia
- lymphoma
Claims 6–7: leukemia and lymphoma subtypes
- Claim 6: leukemia includes
- acute lymphocytic leukemia (ALL)
- acute myelogenous leukemia (AML)
- chronic myelogenous leukemia (CML)
- myeloproliferative neoplasms
- chronic myelomonocytic leukemia
- Claim 7: lymphoma includes
- Hodgkin’s lymphoma
- Non-Hodgkin lymphoma
- T-cell lymphoma
Claim 8–9: MDS restricted to lower-risk by IPSS
- Claim 8 narrows MDS to lower risk MDS.
- Claim 9 specifies lower risk MDS includes:
- low IPSS score
- intermediate 1 IPSS score
This is a meaningful narrowing, because IPSS is a disease stratification tool. Even if a product is used in higher-risk MDS, Claim 8–9 may not be satisfied.
Claim 10: enumerated solid cancer indications
Claim 10 enumerates solid cancers as selected from:
- pancreatic cancer
- ovarian cancer
- peritoneal cancer
- non-small cell lung cancer
- breast cancer
- neuroectodermal tumors
- sarcomas
Practical implication
From an infringement perspective, the “selection” language (“selected from”) matters for claim coverage: it covers any method where the treated cancer is within the enumerated set. If an accused use is outside the listed solid cancers (or uses a solid cancer outside the set), the dependent claims may not read on that indication.
Which elements drive infringement risk: formulation, dose, or AUC equivalence?
Three independent “gates” to infringement
Claim 1 can be reduced to three required gate conditions:
- Dose and content gate: 100 mg cedazuridine + 35 mg decitabine per daily solid oral dosage form.
- Composition gate: the solid oral dosage form “consisting of” the listed excipients.
- PK equivalence gate: daily administration yields a 5-day decitabine AUC equivalent to IV 20 mg/m² given as 1-hour infusion.
- Treatment linkage gate: treating the disorder.
If any gate fails, method infringement is less likely.
Claim 2–10 additional gates
Depending on the target indication (MDS low risk by IPSS, specific leukemia/lymphoma types, or enumerated solid tumors), additional dependent claim elements must be met.
What is the likely relationship to approved cedazuridine/decitabine oral therapy and IV decitabine benchmarks?
The independent claim’s PK comparator is explicit: IV decitabine 20 mg/m² over 1 hour and equivalence measured using 5-day AUC. That structure tracks a common development approach for oral nucleoside analog prodrug/mixture systems: show oral exposure equivalence to IV dosing and then claim treatment methods based on achieving that exposure.
Given that the claimed actives are cedazuridine and decitabine with fixed amounts (100 mg/35 mg), this patent’s scope aligns with a single fixed-dose oral regimen rather than a flexible dosing schedule.
US 12,239,653 claim landscape summary: coverage map by claim tier
| Claim |
What it adds |
Scope impact |
| 1 |
Method for any “decitabine-treatable” disorder using a solid oral dose with exact 100 mg cedazuridine + 35 mg decitabine and specified excipients; plus optional coating; plus 5-day decitabine AUC equivalent to IV 20 mg/m² 1-hour infusion |
Narrow on formulation and PK metric; broad on disorder class until dependent narrowing |
| 2 |
Disorder must be hyperproliferative |
Moderate narrowing |
| 3 |
Disorder must be cancer |
Moderate narrowing |
| 4 |
Cancer restricted to hematological and solid cancers |
Narrows category framing |
| 5 |
Hematological cancer: MDS, leukemia, lymphoma |
Narrows to enumerated hematologic groupings |
| 6 |
Leukemia subtype list |
Further narrowing |
| 7 |
Lymphoma subtype list |
Further narrowing |
| 8–9 |
Lower-risk MDS: low or intermediate 1 IPSS |
Key clinical stratification narrowing |
| 10 |
Solid cancer subtype list |
Further narrowing to enumerated solid tumors |
Patent estate and landscape: what can be inferred from the claim text alone?
The prompt requests “detailed analysis of the scope and claims and patent landscape,” but it provides only the claims for US 12,239,653. No prosecution history, patent citations, related family members, specification details, assignee, filing date, priority date, expiration date, or FDA/Orange Book entry data are provided. Under the constraints, a complete and accurate landscape cannot be built without those facts.
Accordingly, the analysis below is limited strictly to claim-scope implications derived from the provided claim language and does not assert specific litigations, generic competitors, or family-member expirations.
How does US 12,239,653 compare with other typical cedazuridine/decitabine patent types?
Even without external documents, the claim format indicates its place among common IP buckets:
- Unlike a pure composition patent, it is a method-of-treatment claim, not merely a formulation product claim. Infringement is tied to treating a patient, not only manufacturing or possessing the tablet.
- Unlike a pure PK claim, it requires both the dosage form and a clinical treatment linkage.
- Unlike an indication-only claim, it is constrained by formulation composition and exact actives and AUC equivalence.
That combination creates an IP profile that can deter:
- “design-around” by changing excipients or tablet content (composition gate),
- “design-around” by using different dose ratios or different strengths,
- and “design-around” by relying on similar mechanism of action without achieving AUC equivalence.
Key takeaways
- US 12,239,653 is a method-of-treatment patent that covers decitabine treatment through a specific fixed-dose oral solid: 100 mg cedazuridine + 35 mg decitabine, with a “consisting of” excipient list and optional coating.
- The claim’s strongest constraint is pharmacokinetic equivalence: a 5-day decitabine AUC equivalent to IV decitabine 20 mg/m² administered as a 1-hour infusion.
- Dependent claims narrow the disorder from “decitabine-treatable” to hyperproliferative disorder and then to cancer with specific enumerated hematologic and solid tumor lists.
- The claim set includes a clinically specific narrowing for lower-risk MDS defined by IPSS low or intermediate 1.
FAQs
-
Does US 12,239,653 cover uncoated and coated tablets?
Claim 1 allows an “optionally a coating,” so the method is written to cover both, assuming other “consisting of” constraints are satisfied.
-
If an oral cedazuridine/decitabine product matches the same actives but uses different excipients, is it covered?
Claim 1 uses “consisting of” language listing excipients; changing excipients beyond the recited set can avoid the formulation element.
-
Is the claim limited to specific administration days or only to achieving 5-day AUC?
The PK requirement is framed as a 5-day AUC after daily administration, which effectively implies a multi-day dosing context consistent with 5-day treatment exposure.
-
Can treatment of higher-risk MDS fall outside the dependent claims?
Yes. Dependent Claims 8–9 limit to lower risk MDS with IPSS low or intermediate 1.
-
Is this a patent on manufacturing process or on treating patients with the oral dosage form?
It is written as a method of treating claim tied to administering the specified oral solid dosage form and achieving the decitabine AUC equivalence.
References (APA)
- United States Patent 12,239,653. (Provided claim text).
